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BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors 
improve heart failure–associated outcomes in patients with type 2 
diabetes. In patients with heart failure, SGLT2 inhibitors will likely be 
coprescribed with a loop diuretic, but this combined effect is not well-
defined. Our aim was to assess the diuretic and natriuretic effect of 
empagliflozin in combination with loop diuretics.
METHODS: The RECEDE-CHF trial (SGLT2 Inhibition in Combination 
With Diuretics in Heart Failure) was a randomized, double-blind, placebo-
controlled, crossover trial of patients with type 2 diabetes and heart 
failure with reduced ejection fraction taking regular loop diuretic who 
were randomized to empagliflozin 25 mg once daily or placebo for 6 
weeks with a 2-week washout period. The primary outcome was change 
in 24-hour urinary volume from baseline to week 6.
RESULTS: Twenty-three participants (mean age, 69.8 years; 73.9% male; 
mean furosemide dose, 49.6±31.3 mg/d; mean HbA1c, 7.9±3.8%) were 
recruited. Compared with placebo, empagliflozin caused a significant 
increase in 24-hour urinary volume at both day 3 (mean difference, 535 
mL [95% CI, 133–936]; P=0.005) and week 6 (mean difference, 545 
mL [95% CI, 136–954]; P=0.005) after adjustment for treatment order, 
baseline 24-hour urine volume, and percentage change in loop diuretic 
dose. At 6 weeks, empagliflozin did not cause a significant change 
in 24-hour urinary sodium (mean difference, −7.85 mmol/L [95% CI, 
−2.43 to 6.73]; P=0.57). Empagliflozin caused a nonsignificant increase 
in fractional excretion of sodium at day 3, which was absent at week 6 
(mean difference day 3, 0.30% [95% CI, −0.03 to 0.63]; P=0.09; week 
6, 0.11% [95% CI, −0.22 to 0.44]; P>0.99), and a significant increase 
in electrolyte-free water clearance at week 6 (mean difference, 312 mL 
[95% CI, 26–598]; P=0.026) compared with placebo. Empagliflozin also 
caused significant reductions in body weight and serum urate at week 6.
CONCLUSIONS: Empagliflozin caused a significant increase in 24-
hour urine volume without an increase in urinary sodium when used in 
combination with loop diuretic.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: 
NCT03226457.
© 2020 The Authors. Circulation is 
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Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
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that the original work is properly cited.
Natalie A. Mordi, MRCP*
Ify R. Mordi, MD*
Jagdeep S. Singh , MD
Rory J. McCrimmon , MD
Allan D. Struthers, MD
Chim C. Lang , MD 
ORIGINAL RESEARCH ARTICLE
Renal and Cardiovascular Effects of SGLT2 Inhibition 
in Combination With Loop Diuretics in Patients With 








 http://ahajournals.org by on N
ovem
ber 6, 2020
Mordi et al SGLT2 Inhibitors With Diuretics in HF














SGLT2 (sodium-glucose cotransporter-2) inhibitors have demonstrated improved cardiovascular and renal outcomes in patients with type 2 diabetes 
(T2D), most strikingly with a significant reduction in 
hospitalization for heart failure (HF).1–3 Recently, the 
SGLT2 inhibitor dapagliflozin has been shown to cause 
a reduction in death and HF hospitalization in patients 
with HF with reduced ejection fraction irrespective of 
T2D status.4 One notable feature from these outcome 
trials was the evidence of early benefit (<3 months). In 
DAPA-HF (Study to Evaluate the Effect of Dapagliflozin 
on the Incidence of Worsening Heart Failure or Car-
diovascular Death in Patients With Chronic Heart Fail-
ure), the reduction in worsening HF events, defined as 
either an unplanned hospitalization or an urgent visit 
requiring intravenous therapy for HF, was seen as early 
as the first few weeks.4 The mechanism for this is un-
clear, but one possible hypothesis is the diuretic effect 
of SGLT2 inhibition.5–8
The SGLT2 is localized to the renal proximal convo-
luted tubules, acting to reabsorb the majority (≈90%) 
of the filtered glucose coupled with sodium. SGLT2 in-
hibition therefore results in glucosuria, and the ensuing 
osmotic diuresis may potentially be beneficial particu-
larly for those with T2D and HF.6,9 Whether SGLT2 in-
hibitors cause significant natriuresis is less clear, but is 
important in the context of patients with HF who are 
likely to also be prescribed loop diuretics.
Given the improvement in HF-associated outcomes 
seen with SGLT2 inhibitors, the results of DAPA-HF, and 
the recent Food and Drug Administration approval for 
the use of dapagliflozin in patients with HF with reduced 
ejection fraction, the coprescription of loop diuretic and 
SGLT2 inhibitors will become increasingly common,4,10 
and therefore further mechanistic studies are required 
to understand their combined effects. The aim of this 
trial was to explore the effects of the SGLT2 inhibitor 
empagliflozin on diuresis and natriuresis and on the in-
teraction between loop diuretics and SGLT2 inhibitors.
METHODS
Study Design
The study was approved by the East of Scotland Research 
Ethics Service (Regional Ethics Committee reference 16/
ES/0137) and all patients gave written informed consent 
before study inclusion. All data generated or analyzed during 
this study are included in this published article and its supple-
mentary information files.
The full details of the RECEDE-CHF trial (SGLT2 Inhibition in 
Combination With Diuretics in Heart Failure) (NCT03226457) 
methodology have been published.11 In brief, RECEDE-CHF 
was a single-center, randomized, double-blind, placebo-con-
trolled, crossover trial conducted in Tayside, Scotland, to com-
pare the SGLT2 inhibitor empagliflozin with placebo. After 
successful screening for eligibility and safety, participants 
were randomized to either empagliflozin 25 mg/placebo or 
placebo/empagliflozin 25 mg for 6 weeks with a minimum of 
a 2-week washout period between treatment arms. Patients 
were randomized in a 1:1 fashion with group assignment 
masked by use of encapsulated study drug/placebo (Figure 1). 
Randomization was carried out by an independent pharma-
cist with no other trial role, using block randomization of 
treatment order using a validated randomization program. 
Both the investigator and the patient were blinded to the 
treatment order.
Inclusion and Exclusion Criteria
Patients were eligible if they were 18 to 80 years of age with 
previously diagnosed T2D, with a documented diagnosis of 
HF, in New York Heart Association functional Class II or III, 
with previous echocardiographic evidence of HF with left ven-
tricular ejection fraction <50%. HF was deemed to be the 
diagnosis when there was documentation from the treating 
clinician of presentation with symptoms or signs consistent 
with HF requiring treatment with loop diuretics in the pres-
ence of an echocardiogram confirming left ventricular ejec-
tion fraction <50%. Participants were required to be on stable 
doses of furosemide (or alternative loop diuretic) for at least 1 
month before randomization and not have been hospitalized 
for HF for at least 3 months before giving consent.
Patients were excluded if they had systolic blood pressure 
<95 mm Hg at screening visit, had HbA1c <6.0%, had esti-
mated glomerular filtration rate (eGFR) <45 mL/min/73 m2, 
were taking regular thiazide diuretics, or had a diagnosis of 
chronic liver disease or liver enzymes twice the upper limit 
of normal.
Study Procedures
After the randomization visit, participants were given empa-
gliflozin 25 mg or placebo. Participants returned at 3±2 days, 
having completed a 24-hour urine collection before this visit, 
for a study day where they underwent renal physiologic tests 
(RPTs). The RPTs were performed to provide further mechanistic 
Clinical Perspective
What Is New?
• In patients with heart failure and type 2 diabetes 
taking regular loop diuretics, empagliflozin caused 
a significant increase in urine volume at both day 
3 and week 6 compared with placebo, as well 
as a significant increase in electrolyte free water 
clearance.
• Although there was small, nonsignificant increase 
in natriuresis with empagliflozin at day 3, this was 
absent by week 6.
What Are the Clinical Implications?
• These results suggest empagliflozin may have an 
advantageous diuretic profile in patients with type 
2 diabetes and heart failure in addition to loop 
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understanding on the combined effect of administration of 
empagliflozin in addition to furosemide immediately after the 
dose. The specific aim of these RPTs was to study the acute 
effects of empagliflozin versus placebo in the first hour of 
administration on urine volume and urinary sodium excre-
tion. The protocol was also designed to test whether empa-
gliflozin augmented the effect of a bolus of intravenous loop 
diuretic. Full details of the RPTs are described in the previ-
ously published methods article11 and in Table I in the Data 
Supplement. In brief, the RPTs took place over ≈5 hours and 
followed an overhydration protocol. Participants took an oral 
water load (15 mL/kg) and voided urine at 30-minute inter-
vals. After each void of urine, the patient drank a volume of 
water that was equal to the volume of urine voided to induce 
steady-state diuresis and avoid the need for catheterization. 
The participants received empagliflozin 25 mg or placebo at 
150 minutes, with ongoing 30-minute urine collections. One 
hour later (210 minutes), they received a bolus of intrave-
nous furosemide at half their total daily dose, and a further 
2 urine volumes were measured at 30 minutes and 1 hour 
after injection. Intravenous furosemide was administered to 
eliminate variable gut absorption and for practical reasons to 
allow study completion within the set time frame owing to 
the reduced time for peak onset of diuretic effect with intra-
venous administration.11
Patients returned at week 6 having performed another 
24-hour urine collection and underwent another RPT. The 
study drug, empagliflozin 25 mg or placebo, was discontinued 
at this point. The patient then returned after a minimum of a 
2-week washout period (week 9) to begin the second treat-
ment arm of placebo or empagliflozin 25 mg. The 24-hour 
urine collection and RPT was then repeated at week 9+3 days 
and at week 14 for the final study day, when all patients ter-
minated the study drug.
Study Outcomes
The primary outcome of the trial was to assess whether empa-
gliflozin augmented the diuretic effects of loop diuretics as 
measured by the absolute change in 24-hour urine volume 
(mean difference), when compared with placebo, measured at 
week 6.
Secondary outcomes included change in 24-hour urinary 
sodium (mmol/L and mmol/d), fractional excretion of sodium 
(FENa), assessment of electrolyte-free water clearance (mL), 
changes in renal biomarkers (serum creatinine, eGFR, cys-
tatin C, and urine protein/creatinine and albumin/creatinine 
ratios), and change in NT-proBNP (N-terminal pro–B-type 
natriuretic peptide).
FENa was calculated using the following formula:
Fractional Excretion of Sodium FENa   




/00 S x UNa Cr( )
where SCr is the serum creatinine, UNa is the urine sodium, SNa 
is the serum sodium, and UCr is the urine creatinine.
The effect of empagliflozin versus placebo on urinary 
volume, urine sodium, and FENa during the RPTs was also 
assessed. Because of the large volume of multicenter studies 
reporting on the safety and adverse events of SGLT2 inhibitors, 
for this trial the focus was on the effects on coprescription 
with loop diuretic. Adverse event data were also collected.
Statistical Analysis
We hypothesized that changes in urine output seen during 
the RPT would also be extrapolated over the 24-hour urine 
collection period, given the relative urine volume magnitudes. 
We therefore elected to base our sample size calculation on 
the effect of empagliflozin versus placebo in the RPT. A pre-
vious study in which an RPT was performed using a similar 
overhydration protocol reported a mean furosemide-induced 
urinary volume of 920 mL over 1 hour (SD 250 mL). We 
hypothesized that empagliflozin would cause an additional 
20% increase in urinary volume. Twenty-two participants per 
arm were required to detect this difference with an α of 0.05 
and power of 90%. This also gave 80% power (α=0.05) to 
detect a 20% increase in mean furosemide-induced sodium 
excretion of 300 µmol/min (SD 60).12 We decided that because 
Figure 1. The RECEDE-CHF (SGLT2 Inhibition in Combination With Diuretics in Heart Failure) study design.
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the RPT days were likely to be highly intensive for the patients, 
we would also factor in a high dropout rate, and so we ini-
tially planned to recruit 34 patients.
Number and percentage were calculated for discrete vari-
ables. For continuous variables, mean and SD are reported 
where data are evenly distributed and median and interquar-
tile range for non-normally distributed data.
Analyses were performed on the primary and second-
ary measures comparing empagliflozin versus placebo 
and assessed by 2-way analysis of covariance correcting 
for treatment order, baseline value, and any percentage 
change in furosemide dose at the visit. Data for continu-
ous outcome measures were assessed for normality before 
analysis. Transformation of the outcome variables was 
used where necessary where these were not normally dis-
tributed. In analysis of the electrolyte free water clearance 
(cH20e), multiple imputations were used to impute missing 
values because there was >10% missing data. Ten impu-
tations were carried out and pooled results calculated. 
Because 24-hour urine collections were not performed at 
the randomization visit (day 0), values taken from day 3 
of placebo were taken as baseline. For the RPTs, urine vol-
ume, sodium, and FENa at the beginning of the RPT and 
after administration of study drug and furosemide were 
directly compared between empagliflozin and placebo at 
both day 3 and week 6.
RESULTS
Baseline Characteristics
Recruitment is summarized in the Consolidated Stan-
dards of Reporting Trials diagram (Figure 2) and base-
line characteristics are summarized in Table 1.
Between December 2017 and August 2018, 44 pa-
tients were screened for eligibility and 23 patients were 
randomized. The anticipated high dropout from the 
study did not occur, and all patients remained in the 
study for the duration; therefore, for ethical reasons, 
we stopped recruitment at 23 patients, once it became 
clear that we would have an adequate sample to meet 
our prespecified power calculation.
Of the 21 patients who were screen failures, 10 
failed because of HbA1c <6.0%, 7 failed because of 
reduced eGFR, 1 patient was also on a thiazide diuretic, 
1 had started on an SGLT2 inhibitor, 1 was not on stable 
HF therapy (this patient had recently started taking sa-
cubitril/valsartan), and 1 was not able to be randomized 
within 4 weeks as per protocol.
The mean age of the cohort was 69.8±5.7 years 
and the majority of the patients were men (73.9%). As 
per the inclusion criteria, all patients were in New York 
Figure 2. Consolidated Standards of Reporting Trials diagram.
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Heart Association functional class II to III with previous 
echocardiographic evidence of HF with left ventricular 
ejection fraction <50% (47.8% had an ejection fraction 
of 36% to 45%), with a median NT-proBNP of 2381 pg/
mL (range, 1472–7434). All participants were taking fu-
rosemide or equivalent loop diuretic at a mean dose of 
49.6±31.3 mg/d and 87% were taking β-blockers and 
a renin-angiotensin antagonist. A total of 26.1% of pa-
tients recruited had chronic kidney disease (CKD) stage 
3a (eGFR, 45–60 mL/min/1.73 m2). The mean HbA1c 
was 7.9±3.8% (62.7±18.4 mmol/mol), with a mean 
duration of T2D of 8.7±6.3 years. Mean serum creati-
nine level was 87.3 mmol/L±13.6 mmol/L with urinary 
albumin/creatinine ratio 3.2±4.5 mg/mmol. There were 
no participant dropouts.
Twenty-Four–Hour Urine Collection
When compared with placebo, empagliflozin caused a 
significant increase in 24-hour urinary volume at both 
day 3 (mean difference, 535 mL [95% CI, 133–936]; 
P=0.005) and week 6 (mean difference, 545 mL [95% 
CI, 136–954]; P=0.005) when adjusted for treatment 
order, baseline 24-hour urine volume, and percentage 
change in loop diuretic dose (Table 2 and Figure 3A).
There was no significant interaction between treat-
ment order and the primary outcome (P=0.62). There 
was no significant difference in the change in 24-hour 
urinary volume from baseline dependent on the order 
of treatment (mean 246.3 mL in treatment order pla-
cebo/empagliflozin, mean 246.7 mL in treatment order 
empagliflozin/placebo, P>0.99), demonstrating no car-
ryover effect in the primary outcome.
Empagliflozin did not cause a significant change in 
24-hour urinary sodium measured in mmol/L (mean 
difference compared with placebo: day 3, −7.44 
mmol/L [95% CI, −21.75 to 6.88]; P=0.62; week 6: 
−7.85 mmol/L [95% CI, −2.43 to 6.73]; P=0.57) or in 
mmol/d (mean difference: day 3, 33.6 mmol/d [95% 
CI, −11.8 to 79.0]; P=0.22; week 6: 17.9 mmol/d 
[95% CI, −27.2 to 63.0]; P>0.99; Figure 3B and 3C). 
Empagliflozin caused an increase in FENa during the 
24-hour urine collections at day 3 (mean difference, 
0.30% [95% CI, −0.03 to 0.63]; P=0.09) but this 
did not reach significance. There was no significant 
change in FENa as measured at week 6 (mean differ-
ence, 0.11% [95% CI, −0.22 to 0.44]; P>0.99) when 
compared with placebo (Figure 3D).
There was no significant difference in 24-hour urine 
volume, sodium, or FENa stratified by eGFR above or 
below 60 mL/min/1.73 m2 (interaction P values 0.43, 
0.56, and 0.34, respectively).
Compared with placebo, empagliflozin caused a sig-
nificant decrease in 24-hour urinary creatinine at week 
6 (mean difference, −1.66 mmol/L [95% CI, −3.07 to 
−0.25]; P=0.016), with a nonsignificant decrease at day 




Cerebrovascular disease 2 (8.7)
Coronary artery disease 10 (43.5)
First-degree relative with MI/CVA 17 (73.9)
Diabetes
  HbA1c, mmol/mol 62.7±18.4
  HbA1c, % 7.9±3.8
  Duration of type 2 diabetes, y 8.7±6.3
  Insulin 5 (21.7)
  Metformin 16 (69.6)
  Sulfonylurea 4 (17.4)
  Diet controlled 5 (21.7)
Heart failure
  Left ventricular ejection fraction
  ≥45% 7 (30.4)
  36% to 45% 11 (47.8)
  ≤35% 5 (21.7)
  β-blocker 20 (87.0)
  Statin 20 (87.0)
  Mineralocorticoid receptor antagonist 11 (47.8)
  ACEi/ARB/ARNi 20 (87.0)
  ACEi 9 (39.1)
  ARB 8 (34.8)
  ARNi 3 (13.0)
  Loop diuretic 23 (100.0)
  Loop diuretic dose
   ≤40 mg 19 (82.6)
   41 to 80 mg 2 (8.7)
   >80 mg 2 (8.7)
Physical examination
  Weight, kg 94.3±17.0
  Body mass index, kg/m2 33.9±5.6
  Systolic blood pressure, mm Hg 125.2±18.4
  Diastolic blood pressure, mm Hg 70.2±8.9
Laboratory measurements
  NT-proBNP, pg/mL 2381 (1472 to 7434)
  Creatinine, mmol/L 87.3±13.6
  Urea, mmol/L 7.7±2.0
  eGFR, mL/min/1.73 m2
   >60 17 (73.9)
   <45 to 59 6 (26.1)
  uACR, mg/mmol 3.2±4.5
  uPCR, mg/mmol 12.3±9.5
  Serum urate, mmol/L 395.6±88.9
Values are mean±SD or n (%), except NT-proBNP median (interquartile range). 
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; eGFR, estimated 
glomerular filtration; HbA1c, hemoglobin A1c; MI/CVA, myocardial infarction/
cerebrovascular disease; NT-proBNP, N-terminal pro–B-type natriuretic peptide; 
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3 (mean difference, −1.24 mmol/L [95% CI, −2.66 to 
0.18]; P=0.11).
Empagliflozin caused a significant increase in electro-
lyte-free water clearance (cH20e) at week 6 (mean differ-
ence when compared with placebo 312 mL [95% CI, 26–
598]; P=0.026), with a nonsignificant increase at day 3 
(mean difference, 272 mL [95% CI, −18 to 562]; P=0.08).
Empagliflozin did not cause a significant change 
in urinary urea as measured in the 24-hour urine col-
lection at both time points (day 3: mean difference, 
−21.83 mmol/L [CI, −58.99 to 39.19]; P>0.99; week 6: 
mean difference, −3.05 [CI, −40.84 to 34.74]; P>0.99).
Renal Physiology Tests
RPT results are summarized in Figure 4 and Table II in the 
Data Supplement. In the RPTs, there were no significant 
differences in urinary volume, urine sodium, or FENa dur-
ing the first hour (baseline measurement) at day 3 or 
week 6. In the hour after study drug administration, em-
pagliflozin caused a nonsignificant increase in urine vol-
ume at week 6 (mean difference, 110 mL [95% CI, −26 to 
246]; P=0.19). At week 6, patients taking empagliflozin 
had an increased FENa in the hour after administration of 
loop diuretic compared with when taking placebo, but 
again this did not reach statistical significance (mean dif-
ference, 2.51% [95% CI, −0.27 to 5.28]; P=0.10).
Secondary Outcomes and Additional 
Measures
Empagliflozin did not cause any significant change 
in markers of renal function (serum creatinine, urine 
protein-to-creatinine  ratio, urine albumin-to-creati-
nine ratio, or cystatin C) compared with placebo at day 
3 or week 6 (Table III in the Data Supplement). A total 
of 12 (52.2%) participants saw a drop in eGFR category 
(ie, CKD stage 2 to CKD stage 3a by day 3 of empa-
gliflozin compared with 7 in the placebo arm; P=0.13). 
However, this was transient, and renal function recov-
ered in the majority of patients in the empagliflozin 
arm, with only 6 participants having a persistent reduc-
tion in CKD category versus 5 on placebo (P=0.73).
There were no significant differences in intravascular 
volume markers (serum urea [Table 3 and Figure 5A], 
systolic blood pressure [Figure  5B], and serum hema-
tocrit [Figure 5C]). There was no significant change in 
NT-proBNP or serum β-hydroxybutyrate.
Empagliflozin caused significant weight loss com-
pared with placebo at week 6 (day 3: mean difference, 
−1.00 kg [95% CI, −2.15 to 0.14]; P=0.12; week 6: 
mean difference, −1.71 kg [95% CI, −2.90 to −0.53]; 
P<0.001; Figure 5D). Empagliflozin also caused a signif-
icant reduction in serum urate by week 6 (day 3: mean 
difference, −28.6 [95% CI, −68.5 to 11.2]; P=0.33; 
week 6: mean difference, −67.2 [95% CI, −107.0 to 
−27.4]; P<0.001).
Clinical Events
Clinical events are summarized in Table IV in the Data 
Supplement. Five patients required a 50% reduction of 
their furosemide dose while on the active treatment arm 
of empagliflozin by day 3 (1 patient had a 50% dose 
reduction from 80 mg to 40 mg once daily, 4 patients 
50% reduction of 40 mg to 20 mg once daily) because 
Table 2. Change in 24-Hour Urine Volume, 24-Hour Urinary Sodium (uNa) mmol/L, mmol/d, and Fractional Excretion of Sodium (FENa %), 24-Hour 
Urinary Creatinine, and Electrolyte Free Water Clearance (cH20e) With Placebo and Empagliflozin at Day 3 and Week 6 Adjusted for Treatment 
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of improvement in their clinical volume status. Of those 
patients who had their loop diuretic reduced, mean 
weight loss at day 3 was 2.22±1.19 kg. On discontinu-
ation of empagliflozin, they needed to have their usual 
dose of loop diuretic reinstated because of weight gain 
or other clinical signs of increased congestion (within 
the blinded period). Two participants required their usu-
al oral loop diuretic to be doubled after discontinuation 
of the active treatment arm with empagliflozin.
Two participants who had been on an unchanged dose 
of loop diuretic throughout the trial had hospital admis-
sions with decompensated HF on discontinuation of empa-
gliflozin. There were no episodes of hyponatremia or hypo-
kalemia. There were no incidences of diabetic ketoacidosis 
or episodes of severe hypoglycemia (ie, episodes requiring 
assistance from another person to treat). Two patients ex-
perienced an acute decline in renal function as measured 
by a serum creatinine rise >26 mmol/L in 48 hours13 by day 
3 of empagliflozin, which resolved by week 6.
DISCUSSION
In this randomized, controlled trial of the effects of 
SGLT2 inhibition in addition to loop diuretic in patients 
with HF with T2D, we found that within 6 weeks em-
pagliflozin caused a significant increase in total urine 
volume without a significant increase in urinary sodium 
or FENa compared with placebo. We also found that 
empagliflozin caused a significant increase in electro-
lyte free water clearance. Empagliflozin also caused sig-
nificant weight loss and overall changes in clinical sta-
tus necessitating a reduction in furosemide dose. There 
were no significant changes in markers associated with 
intravascular volume change, including serum urea, he-
matocrit, or systolic blood pressure.
After DAPA-HF, SGLT2 inhibitors are increasingly 
being considered as an HF medication rather than 
as strictly antihyperglycemic therapy.4 The early ben-
efit improvement in HF outcomes seen has raised the 
possibility that the osmotic diuresis caused by SGLT2 
inhibitors might be one mechanism contributing to 
improved outcomes by improving ventricular loading 
conditions.9 Our study sheds light on this potential 
diuretic effect; our findings of a significant increase 
in urine volume without a significant increase in na-
triuresis with associated significant weight loss could 
be particularly beneficial in patients with HF in whom 
traditional strategies for reducing fluid overload—for 
Figure 3. Change in urine volume, urine sodium, and fractional excretion of sodium from placebo day 3.
Change in urine volume (A), urine sodium (B and C), and fractional excretion of sodium (D) from placebo day 3. P values refer to the mean difference between 
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example, combining loop and thiazide diuretics—can 
induce hyponatremia.14
We found that empagliflozin caused a significant 
increase in 24-hour urine volume but did not have a 
significant effect on urine volume or sodium during 
the RPTs immediately after a single dose. This has been 
reported in other studies, although we have now ex-
tended this finding to patients with HF with T2D on 
loop diuretic, including in those with eGFR 45 to 60 
mL/min/1.73 m2. In a trial of 36 patients with T2D, 
canagliflozin caused an increase in total urine volume 
without any significant change in plasma volume at 12 
weeks.15 In another small observational study in patients 
with CKD, dapagliflozin was associated with preferen-
tial reduction in extracellular water in comparison to fu-
rosemide.16 As a potential HF therapy, SGLT2 inhibitors 
could be frequently prescribed alongside loop diuretics, 
but there are little data on coadministration. A study 
of 42 healthy volunteers randomized to dapagliflozin, 
bumetanide, or combination therapy found that the 
combination of dapagliflozin and bumetanide caused 
a significant increase in urine volume, but not urinary 
sodium, compared with bumetanide alone.17 The au-
thors also found that there was no significant change 
in natriuresis after the first dose of dapagliflozin, sug-
gesting that there is an adaptive, synergistic increase in 
natriuresis over the first week.
Griffin et al18 recently demonstrated that empa-
gliflozin monotherapy caused a modest natriuresis com-
pared with placebo as measured by the FENa, which 
was significant at 3 hours after drug administration but 
not at 1.5 hours. They also reported a synergistic natri-
uretic effect when empagliflozin was given alongside 
intravenous loop diuretic. We did not note a significant 
Figure 4. Urine volume and fractional excretion of sodium during the renal physiologic test (RPT).
Mean and SD of urine volume (top row) and fractional excretion of sodium (bottom) at baseline and after administration of empagliflozin (Empa)/placebo and 
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change in FENa at 2 hours after empagliflozin or 1 hour 
after intravenous furosemide on the RPT days. It is pos-
sible that we may have seen an increase in FENa after a 
longer duration. Nevertheless, in the 24-hour urine col-
lections, we also did not find an increase in natriuresis 
as demonstrated by mmol/L or mmol/d, and although 
there was a nonsignificant increase in FENa at day 3 
caused by empagliflozin, this was absent by week 6. 
Our data are complementary to those of Griffin et al,18 
and the differences in FENa between our study and that 
by Griffin et al18 may reflect the differing time points 
studied. In the study by Griffin et al,18 the largest ef-
fect of empagliflozin on FENa was beyond 3 hours at 
day 1, whereas at day 14, the increase in FENa with 
empagliflozin compared with placebo was attenuated. 
In a single-blind study, Blau et al19 found that although 
canagliflozin caused a significant increase in natriure-
sis at 24 hours, urine sodium had returned to baseline 
by 96 hours. A study by Opingari et al20 also did not 
demonstrate a significant change in FENa at 6 months 
in patients with T2D and established cardiovascular dis-
ease treated with empagliflozin when compared with 
placebo, supporting the theory that any natriuresis that 
might be caused by empagliflozin is perhaps transient 
and only present very early. This may be attributable to 
compensatory mechanisms that increase sodium reab-
sorption at other nephron sites.
FENa is a well-used calculation to quantify renal 
sodium handling, by normalizing sodium excretion by 
correcting for urinary and serum creatinine. After drug 
initiation, SGLT2 inhibitors are often associated with 
an initial increase in serum creatinine.1,2,6,21 Because 
creatinine filtration can be affected by SGLT2 initia-
tion, FENa may be difficult to interpret in this context. 
We saw a nonsignificant increase in serum creatinine 
with empagliflozin that had resolved by week 6, a 
pattern well-described with SGLT2 inhibitors. Empa-
gliflozin also caused a significant decrease in 24-hour 
urinary creatinine, which would also lead to an in-
crease in calculated FENa.
Recent work from Hallow et al,22 using mathemati-
cal modeling in healthy participants after ingestion of 
SGLT2 inhibitor (dapagliflozin) or loop diuretic (bu-
metanide), suggested that SGLT2 inhibitors may pro-
vide a more selective reduction in interstitial fluid when 
compared with other conventional diuretics.9 The au-
thors found that dapagliflozin caused an increase in 
electrolyte-free water clearance without a significant 
increase in total free water clearance, in contrast to 
bumetanide (which also caused an increase in total 
free water clearance). They suggested that this might 
result in a greater reduction in interstitial fluid volume 
compared with the intravascular compartment, possibly 
influenced by the peripheral sequestration of osmoti-
cally inactive sodium.22 In RECEDE-CHF, we also found 
a significant increase in electrolyte-free water clearance 
by week 6 in patients with HF, which if representative 
of a preferential loss of interstitial fluid would clearly be 
beneficial in HF.9,19,22 The hypothesis of SGLT2 inhibitor–
induced preferential loss of fluid from the interstitial 
rather than the intravascular space remains speculative 
and cannot be directly inferred from our study.
We had some secondary findings that could be 
considered beneficial. Patients required a reduction 
in loop diuretic dose, which was also reported in the 
REFORM trial (Research Into the Effect of SGLT2 Inhi-
bition on Left Ventricular Remodelling in Patients With 
Heart Failure and Diabetes Mellitus).23 After cessation 
Table 3. Change in Weight, Hematocrit, Urate, Systolic Blood Pressure, NT-proBNP (N-terminal pro–B-type natriuretic peptide), Serum Urea, and β-
Hydroxybutyrate (βhb) With Placebo and Empagliflozin From Day 0 to Day 3 and Week 6 Adjusted for Treatment Order and Any Percentage Change 
in Loop Diuretic Dose
Values
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of empagliflozin, some patients also noted increasing 
congestion requiring an increase in loop diuretic or had 
a HF hospitalization, although our trial was clearly not 
powered for clinical outcomes. In a post hoc analysis of 
DAPA-HF, the benefit of dapagliflozin was consistent ir-
respective of baseline diuretic use; however, in patients 
on a diuretic, adverse events related to volume depletion 
occurred more frequently with dapagliflozin compared 
with placebo.24 In addition, renal adverse events were 
less common with dapagliflozin compared with placebo 
in those not on a diuretic at baseline.24 These findings 
underscore the need for vigilance regarding volume 
status and judicious adjustment of loop diuretic doses 
when initiating an SGLT2 inhibitor in patients with HF.
The finding of a significant reduction in serum urate 
with empagliflozin has been documented previously; 
however, it is reassuring that we also observed this in 
patients with HF taking a regular loop diuretic.25 This 
may again provide evidence to favor use of SGLT2 in-
hibitors as an add-on therapy in patients with HF with 
fluid congestion rather than thiazide diuretics or other 
alternatives.
We did not find a significant change in NT-proB-
NP at 3 days or 6 weeks. Although this is perhaps 
counterintuitive given the overwhelming evidence of 
benefit of SGLT2 inhibitors in HF, this has actually also 
been reported in other trials including patients with 
chronic26 and acute HF.27 In both of these studies, SGLT2 
inhibition led to a clinically important benefit despite the 
absence of a change in natriuretic peptide levels. This 
may in part be attributable to weight loss, which has 
been reported as causing an increase in NT-proBNP.28,29
Our findings may also have clinical implications in 
patients with decompensated HF and fluid overload. 
At this time, sequential nephron blockade with thia-
zide-like diuretics used in combination with loop di-
uretics is often used to overcome diuretic resistance 
in acute decompensated chronic HF.30 However, this 
strategy does not always work and is associated with 
the hazards of hypokalemia, hyponatremia, hypoten-
sion, and renal failure. We demonstrated that diuresis 
without significant natriuresis is quickly achieved by 
day 3. Potentially, this highlights the SGLT2 inhibitor as 
an alternative to the thiazide-like diuretics in patients 
who may have evidence of fluid retention resistance to 
loop diuretics alone.
Our study has some limitations. It was a small, sin-
gle-center crossover study with participants who were 
Figure 5. Change in serum urea, systolic blood pressure, hematocrit, and body weight.
Change in serum urea (A), systolic blood pressure (SBP; B), hematocrit (C), and body weight (D). P values refer to the mean difference between empagliflozin and 
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predominantly male and with a midrange ejection frac-
tion. The crossover design was a strength, with each pa-
tient acting as their own control in a blinded study. The 
dose investigated in this trial was 25 mg empagliflozin 
once daily, whereas in routine clinical practice the 10 
mg dose is most commonly used; however, in EMPA-
REG OUTCOME (BI 10773 [Empagliflozin] Cardiovas-
cular Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients), no difference in the primary outcome was re-
ported between the 2 treatment groups of 10 mg and 
25 mg.1 At the time we conceived the study (before the 
publication of EMPA-REG OUTCOME), we hypothesized 
that there might be a dose–response effect and there-
fore chose the 25 mg dose in this study. On the day 
of the 24-hour urine collection, we asked participants 
to restrict sodium intake to 2 g/d and fluid intake to 
2 L/d; however, we could not enforce this because pa-
tients were not admitted to hospital but remained at 
home. Patients attended the RPT days after an overnight 
fast to minimize any variations in dietary glucose intake. 
There was no dietary restriction placed on participants 
while the 24-hour urine collection was performed, and 
any variation in glucose control may have modified the 
urinary responses. The effect of glucosuria from SGLT2 
inhibition is well-described in the literature18,20,31 and as 
such we did not measure urine glucose in this study. 
Given that we demonstrated diuresis in the absence of 
significant natriuresis, it would have been interesting to 
identify whether there was an association between glu-
cosuria and 24-hour urine volume. Because of time con-
straints during the RPT days, the patients were observed 
for only 2 hours after administration of investigational 
medical product (placebo or empagliflozin) and 1 hour 
after administration of intravenous furosemide. Any 
significant diuretic or natriuretic effect may have not 
been observed during this short time frame, and might 
have been seen with a longer duration. Assessment of 
plasma renin activity would also have been of interest 
in exploring intravascular volume, although this may 
have been influenced by high use of renin-angiotensin-
aldosterone inhibitors in patients with HF. It is unclear 
whether the changes we saw at 6 weeks would persist 
for a longer time. One observational of study of pa-
tients with T2D, but without HF, reported a reduction 
in extracellular water at day 3, which had returned to 
baseline values by 3 months.32
Conclusions
In the RECEDE-CHF trial, we found that in patients with 
T2DM and HF taking regular furosemide, 6 weeks of 
treatment with empagliflozin caused a significant in-
crease in 24-hour urine volume without an increase in 
urinary sodium compared with placebo. Empagliflozin 
also caused a significant increase in electrolyte-free wa-
ter clearance, significant weight loss, and reduced loop 
diuretic requirement. These findings, combined with a re-
duction in serum uric acid and no significant renal impair-
ment or electrolyte disturbance, provide further insight 
into the mechanism of the diuretic effect of empagliflozin 
and suggest that the combination of loop diuretic and 
SGLT2 inhibition could have a beneficial role in HF.
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